The Disease Interception Accelerator is a partnership with UbiVac , a privately held, clinical, and immunological company that develops immunotherapy aimed at blocking oral / opharyngeal cancer .
Collaborating in more than 150 markets.
By clicking on a link below, you may enter a different part of this website, or a website outside of Janssen.com.
These sections or websites are governed by their own Legal and Privacy Policies.
Global
Asia Pacific
Europe, Middle East & Africa (EMEA)
Latin America
Home › 구강 구인두암
구강 구인두암
Partnerships to Prevent Oral / Oral Pain Cancer